A model for persistent infection with Epstein-Barr virus: the stealth virus of human B cells.
暂无分享,去创建一个
[1] J. Banchereau,et al. Interleukin 10 and transforming growth factor beta cooperate to induce anti-CD40-activated naive human B cells to secrete immunoglobulin A , 1992, The Journal of experimental medicine.
[2] D. Thorley-Lawson,et al. EBV persistence in memory B cells in vivo. , 1998, Immunity.
[3] R. Schooley,et al. BLAST-2 [EBVCS], an early cell surface marker of human B cell activation, is superinduced by Epstein Barr virus. , 1985, Journal of immunology.
[4] I. Maclennan,et al. A subset of CD4+ memory T cells contains preformed CD40 ligand that is rapidly but transiently expressed on their surface after activation through the T cell receptor complex , 1995, The Journal of experimental medicine.
[5] E. Reddy,et al. Transducers of life and death: TNF receptor superfamily and associated proteins. , 1996, Oncogene.
[6] A. Levine,et al. Expression of the BNLF-1 oncogene of Epstein-Barr virus in the skin of transgenic mice induces hyperplasia and aberrant expression of keratin 6 , 1990, Cell.
[7] N. Ling,et al. B cell proliferation in follicles, germinal centre formation and the site of neoplastic transformation in Burkitt's lymphoma. , 1988, Current topics in microbiology and immunology.
[8] Gwyn T. Williams,et al. Activation of Epstein–Barr virus latent genes protects human B cells from death by apoptosis , 1991, Nature.
[9] D. Gray,et al. T cell memory is short-lived in the absence of antigen , 1988, Nature.
[10] E. Kremmer,et al. The Epstein‐Barr virus nuclear antigen 2 interacts with an EBNA2 responsive cis‐element of the terminal protein 1 gene promoter. , 1993, The EMBO journal.
[11] Qingxue Li,et al. Epstein-Barr virus uses HLA class II as a cofactor for infection of B lymphocytes , 1997, Journal of virology.
[12] D. Thorley-Lawson,et al. Identification and isolation of the main component (gp350-gp220) of Epstein-Barr virus responsible for generating neutralizing antibodies in vivo , 1982, Journal of virology.
[13] J. Banchereau,et al. The CD40 antigen and its ligand. , 1994, Annual review of immunology.
[14] D. Thorley-Lawson,et al. All three domains of the Epstein-Barr virus-encoded latent membrane protein LMP-1 are required for transformation of rat-1 fibroblasts , 1993, Journal of virology.
[15] K. Rajewsky,et al. Maintenance of B-cell memory by long-lived cells generated from proliferating precursors , 1990, Nature.
[16] N. Raab-Traub,et al. Epstein-Barr virus replication in oropharyngeal epithelial cells. , 1984, The New England journal of medicine.
[17] E. Cesarman,et al. Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of posttransplantation lymphoproliferative disorders. , 1995, Blood.
[18] D. Thorley-Lawson,et al. Early events in Epstein-Barr virus infection provide a model for B cell activation , 1985, The Journal of experimental medicine.
[19] W. Hammerschmidt,et al. Genetic analysis of immortalizing functions of EpsteinBarr virus in human B lymphocytes , 1989, Nature.
[20] H. Cen,et al. EBV gene expression, EBNA antibody responses and EBV+ peripheral blood lymphocytes in post-transplant lymphoproliferative disease. , 1994, Leukemia & lymphoma.
[21] P. L. Deininger,et al. DNA sequence and expression of the B95-8 Epstein—Barr virus genome , 1984, Nature.
[22] A. Rickinson. Virology: Epstein–Barr virus in epithelium , 1984, Nature.
[23] C. Arpin,et al. Germinal center development , 1997, Immunological reviews.
[24] G. Peters,et al. EBNA‐2 and EBNA‐LP cooperate to cause G0 to G1 transition during immortalization of resting human B lymphocytes by Epstein‐Barr virus. , 1994, The EMBO journal.
[25] R. Osamura,et al. Reticular crypt epithelium and intra‐epithelial lymphoid cells in the hyperplastic human palatine tonsil: An immunohistochemical analysis , 1995, Pathology international.
[26] J. Hsieh,et al. EBNA-2 upregulation of Epstein-Barr virus latency promoters and the cellular CD23 promoter utilizes a common targeting intermediate, CBF1 , 1994, Journal of virology.
[27] J. Burrows,et al. Evolutionary dynamics of genetic variation in Epstein-Barr virus isolates of diverse geographical origins: evidence for immune pressure-independent genetic drift , 1997, Journal of virology.
[28] L. Young,et al. Epstein-Barr virus and Hodgkin's disease: transcriptional analysis of virus latency in the malignant cells , 1993, The Journal of experimental medicine.
[29] L. Lanier,et al. CD28 interaction with B7 costimulates primary allogeneic proliferative responses and cytotoxicity mediated by small, resting T lymphocytes , 1992, The Journal of experimental medicine.
[30] E. Kieff,et al. Nucleotide sequence of an mRNA transcribed in latent growth-transforming virus infection indicates that it may encode a membrane protein , 1984, Journal of virology.
[31] G. Klein. Viral latency and transformation: The strategy of Epstein-Barr virus , 1989, Cell.
[32] Stefan Imreh,et al. Inhibition of antigen processing by the internal repeat region of the EpsteinBarr virus nuclear antigen-1 , 1995, Nature.
[33] C. Ware,et al. The Epstein-Barr virus transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family , 1995, Cell.
[34] D. Thorley-Lawson,et al. Detection of the latent form of Epstein-Barr virus DNA in the peripheral blood of healthy individuals , 1996, Journal of virology.
[35] J. Hsieh,et al. Truncated mammalian Notch1 activates CBF1/RBPJk-repressed genes by a mechanism resembling that of Epstein-Barr virus EBNA2 , 1996, Molecular and cellular biology.
[36] E. Kremmer,et al. B‐cell proliferation and induction of early G1‐regulating proteins by Epstein‐Barr virus mutants conditional for EBNA2. , 1995, The EMBO journal.
[37] J. Sample,et al. Transcription start sites downstream of the Epstein-Barr virus (EBV) Fp promoter in early-passage Burkitt lymphoma cells define a fourth promoter for expression of the EBV EBNA-1 protein , 1996, Journal of virology.
[38] V. Baichwal,et al. Transformation of Balb 3T3 cells by the BNLF-1 gene of Epstein-Barr virus. , 1988, Oncogene.
[39] W. Hammerschmidt,et al. Epstein–Barr virus‐mediated B‐cell proliferation is dependent upon latent membrane protein 1, which simulates an activated CD40 receptor , 1998, The EMBO journal.
[40] G. Nemerow,et al. Identification and characterization of the Epstein-Barr virus receptor on human B lymphocytes and its relationship to the C3d complement receptor (CR2) , 1985, Journal of virology.
[41] J. Salisbury,et al. Epstein-Barr virus latent membrane protein does not inhibit differentiation and induces tumorigenicity of human epithelial cells , 1997, Oncogene.
[42] J. Yates,et al. Stable replication of plasmids derived from Epstein–Barr virus in various mammalian cells , 1985, Nature.
[43] J. Pagano,et al. Reciprocal regulation of the Epstein-Barr virus BamHI-F promoter by EBNA-1 and an E2F transcription factor , 1994, Molecular and cellular biology.
[44] D. Rowe,et al. Epstein-Barr virus latent messages with shuffled leader exons: remnants of circumgenomic transcription? , 1995, Journal of virology.
[45] M. Sandberg,et al. Characterization of LMP-1's association with TRAF1, TRAF2, and TRAF3 , 1997, Journal of virology.
[46] H. Stein,et al. Strict lymphotropism of Epstein-Barr virus during acute infectious mononucleosis in nonimmunocompromised individuals. , 1997, Blood.
[47] R. Schooley,et al. Epstein-Barr virus superinduces a new human b cell differentiation antigen (B-LAST 1) expressed on transformed lymphoblasts , 1982, Cell.
[48] H. Stein,et al. Morphology, immunophenotype, and distribution of latently and/or productively Epstein-Barr virus-infected cells in acute infectious mononucleosis: implications for the interindividual infection route of Epstein-Barr virus. , 1995, Blood.
[49] J. Banchereau,et al. Five human mature B cell subsets. , 1994, Advances in experimental medicine and biology.
[50] D. Thorley-Lawson,et al. Identification of the site of Epstein-Barr virus persistence in vivo as a resting B cell , 1997 .
[51] T. Crook,et al. Epstein-Barr virus nuclear antigen (EBNA)3C is an immortalizing oncoprotein with similar properties to adenovirus E1A and papillomavirus E7. , 1996, Oncogene.
[52] J. Banchereau,et al. Germinal Center Founder Cells Display Propensity for Apoptosis before Onset of Somatic Mutation , 1997, The Journal of experimental medicine.
[53] Q Y Yao,et al. Epstein-Barr virus latent gene transcription in nasopharyngeal carcinoma cells: coexpression of EBNA1, LMP1, and LMP2 transcripts , 1992, Journal of virology.
[54] D. Fearon,et al. Functional dissection of the CD21/CD19/TAPA-1/Leu-13 complex of B lymphocytes , 1993, The Journal of experimental medicine.
[55] E. Kieff,et al. Epstein-Barr virus nuclear protein 2 mutations define essential domains for transformation and transactivation , 1991, Journal of virology.
[56] E. Kremmer,et al. Immunohistochemical Detection of the Epstein-Barr Virus–Encoded Latent Membrane Protein 2A in Hodgkin's Disease and Infectious Mononucleosis , 1997 .
[57] B. Griffin,et al. Epstein-Barr virus latent gene expression during the initiation of B cell immortalization. , 1989, The Journal of general virology.
[58] J. Banchereau,et al. Memory B Cells Are Biased Towards Terminal Differentiation: A Strategy That May Prevent Repertoire Freezing , 1997, The Journal of experimental medicine.
[59] E. Lennette,et al. Replication of Epstein-Barr virus within the epithelial cells of oral "hairy" leukoplakia, an AIDS-associated lesion. , 1985, The New England journal of medicine.
[60] J. Banchereau,et al. Human germinal center B cells express the apoptosis-inducing genes Fas, c-myc, P53, and Bax but not the survival gene bcl-2 , 1996, The Journal of experimental medicine.
[61] E. Kieff,et al. Epstein-Barr virus latent membrane protein (LMP1) and nuclear proteins 2 and 3C are effectors of phenotypic changes in B lymphocytes: EBNA-2 and LMP1 cooperatively induce CD23 , 1990, Journal of virology.
[62] D. Rowe,et al. Epstein-Barr virus latent gene expression in uncultured peripheral blood lymphocytes , 1992, Journal of virology.
[63] D. Baltimore,et al. Localization of the Major NF-κB-activating Site and the Sole TRAF3 Binding Site of LMP-1 Defines Two Distinct Signaling Motifs* , 1997, The Journal of Biological Chemistry.
[64] M. Ueffing,et al. Latent membrane protein 1 of Epstein–Barr virus mimics a constitutively active receptor molecule , 1997, The EMBO journal.
[65] M. Hammarskjöld,et al. Epstein-Barr virus latent membrane protein transactivates the human immunodeficiency virus type 1 long terminal repeat through induction of NF-kappa B activity , 1992, Journal of virology.
[66] K. Rajewsky,et al. Human Immunoglobulin (Ig)M+IgD+ Peripheral Blood B Cells Expressing the CD27 Cell Surface Antigen Carry Somatically Mutated Variable Region Genes: CD27 as a General Marker for Somatically Mutated (Memory) B Cells , 1998, The Journal of experimental medicine.
[67] D. Gray,et al. B‐T Lymphocyte Interactions in the Generation and Survival of Memory Cells , 1996, Immunological reviews.
[68] D. Thorley-Lawson,et al. Is EBV persistence in vivo a model for B cell homeostasis? , 1996, Immunity.
[69] E. Kieff,et al. The last seven transmembrane and carboxy-terminal cytoplasmic domains of Epstein-Barr virus latent membrane protein 2 (LMP2) are dispensable for lymphocyte infection and growth transformation in vitro , 1993, Journal of virology.
[70] W. Kolch,et al. Epstein–Barr virus latent membrane protein‐1 triggers AP‐1 activity via the c‐Jun N‐terminal kinase cascade , 1997, The EMBO journal.
[71] K. Rajewsky,et al. The origin of Hodgkin and Reed/Sternberg cells in Hodgkin's disease. , 1998, Annual review of immunology.
[72] D. Thorley-Lawson,et al. A novel form of Epstein-Barr virus latency in normal B cells in vivo , 1995, Cell.
[73] K. Rajewsky,et al. In Vivo Ablation of Surface Immunoglobulin on Mature B Cells by Inducible Gene Targeting Results in Rapid Cell Death , 1997, Cell.
[74] D. Goeddel,et al. The TNF receptor 1-associated protein TRADD signals cell death and NF-κB activation , 1995, Cell.
[75] K. Rajewsky,et al. Evidence for a large compartment of IgM-expressing memory B cells in humans. , 1997, Blood.
[76] J. Spencer,et al. Human marginal-zone B cells. , 1998, Immunology today.
[77] S. T. Liu,et al. Identification of a novel promoter located within the Bam HI Q region of the Epstein-Barr virus genome for the EBNA 1 gene. , 1995, DNA and cell biology.
[78] Kenji Matsuno,et al. Notch signaling. , 1995, Science.
[79] D. Choquet,et al. The (YXXL/I)2 signalling motif found in the cytoplasmic segments of the bovine leukaemia virus envelope protein and Epstein‐Barr virus latent membrane protein 2A can elicit early and late lymphocyte activation events. , 1993, The EMBO journal.
[80] G. Nemerow,et al. Identification of an epitope in the major envelope protein of Epstein-Barr virus that mediates viral binding to the B lymphocyte EBV receptor (CR2) , 1989, Cell.
[81] M. Perricaudet,et al. A spliced Epstein‐Barr virus gene expressed in immortalized lymphocytes is created by circularization of the linear viral genome. , 1988, The EMBO journal.
[82] I. Ernberg,et al. Epstein-Barr virus: adaptation to a life within the immune system. , 1994, Trends in microbiology.
[83] E. Kieff,et al. An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells , 1985, Cell.
[84] J. Banchereau,et al. Generation of memory B cells and plasma cells in vitro , 1995, Science.
[85] S. Speck,et al. Alternative splicing dictates translational start in Epstein‐Barr virus transcripts. , 1990, The EMBO journal.
[86] E. Kieff,et al. Integral membrane protein 2 of Epstein-Barr virus regulates reactivation from latency through dominant negative effects on protein-tyrosine kinases. , 1995, Immunity.
[87] E. Kieff,et al. Epstein-Barr virus nuclear antigen 2 transactivates latent membrane protein LMP1 , 1990, Journal of virology.
[88] C. Rooney,et al. Influence of Burkitt's lymphoma and primary B cells on latent gene expression by the nonimmortalizing P3J-HR-1 strain of Epstein-Barr virus , 1989, Journal of virology.
[89] E. Kieff,et al. Localization of Epstein-Barr virus cytotoxic T cell epitopes using recombinant vaccinia: implications for vaccine development , 1992, The Journal of experimental medicine.
[90] S. Anderson,et al. Epstein-Barr virus LMP2A drives B cell development and survival in the absence of normal B cell receptor signals. , 1998, Immunity.